Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (January 2024)
52 slides from Genprex's investor presentation, Jan 5, 2024
Slide 1: Pioneering Gene Therapies for Patients in Need
€ ) Genprex’ Pioneering Gene Therapies for Patients in Need January 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained inthis presentation regarding matters that are not historical facts fare “Yorwardlooking statements" within the meaning of the Prvate Secures Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual resuts m
Slide 3: Our Mission
Our Mission Advancing novel gene therapies for patients afflicted with cancer or diabetes. © Genprex
Slide 4: Program Highlights
Program Highlights ONCOLOGY DIABETES ® Non-viral gene therapy platform So) Addressing both Type 1 and Type 2 diabetes with AAV gene therapy Novel approach using systemic gene therapy to replace tumor suppressor genes for cancer in @® Novel infusion process delivers genes to pancreas humans a Demonst
Slide 5: Research and Development Pipeline
Research and Development Pipeline [srs ie > g > § 9 Se 7 —) ‘oTven OUAEETES TECHNOLOGIES > © Genprex
Slide 6: Oncology
Q ONCOLOGY REPROGRAMMING THE COURSE OF CANCER rye) www.genprex.com
Slide 7: Tumor Suppressor Genes Deleted During Cancer Development
Tumor Suppressor Genes Deleted During Cancer Development Why TUSC2? 0 Tumor suppressor genes are deleted early during cancer development ‘© 82% of allnon-small cell lung cancers and 100% of all small-cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein -© Loss or reduction o
Slide 8: Regorsa Targets Cancer At Its Core
Regorsa® Targets Cancer At Its Core | Controls Cell Signaling Pan-kinase inhibition decreases cancer cell proliferation © Genprex Stimulates Apoptotic Pathways Leadsto programmed cancer cell death Multiple anti-cancer mechanisms of action. g Modulates Immune Response Promotes immune activity against
Slide 9: Our Cancer Treatment Approach
Our Cancer Treatment Approach Tumor suppressor genes are deleted early during cancer development. Our method of treating cancer is to reintroduce tumor suppressor genes to patients. © Genprex Tumor Suppressor Gene in a DNA Plasmid We have rights to tumor suppressor genes that may have cancer-fightin
Slide 10: Novel Platform to Treat Cancer
Novel Platform to Treat Cancer © Genprex Systemic Gene Therapy Platform: ONCOPREX® Nanoparticle Delivery System Genes Allows for delivery of TUSC2 and NPRL2 genes and potentiallya variety of other genes Synergies Can be usedin combinationwith other cancer therapies such as Tagrisso®, Keytruda® and T
Slide 11: Oncoprex Nanoparticle Delivery System
Oncoprex® Nanoparticle Renee . = ., positively-charged lipid Delivery System nanoparticle (LNP) is systemically delivered. ° REQORSA® IMMUNOGENE THERAPY tumor 0 j suppressor mR Tumor suppressor gene protein Plasmid with TUSC2 gene, >@ O Genprex: Cationic lipid nanoparticle carries drug to tumors.
Slide 12: Selective Uptake of Reqorsa
Selective Uptake REQORSA Targets Cancer Cells of Reqorsa® Pretreatment Biopsies Posttreatment Biopsies REQORSAis designed to deliver the functioning TUSC2 gene to cancer cells while minimizing its uptake by normal tissue. Patient 1 (02mgfka) o Tumor biopsy studies show that, in three © patients, the
Slide 13: Lung Cancer: By the Numbers
Lung Cancer: By the Numbers 127K $48B e e U.S. Annual Global Lung Global Mortality Cancer Incidence Market More than two million new cases per year worldwide? More than 127,000 deaths per year in the US Global market is projected togrow from $183 billion in 2018 to $48.7 billion by 20262. © Genprex
Slide 14: Drug resistance to Tagrisso, Keytruda and Tecentriq is inevitable
For most patients, drug resistance to Tagrisso®, Keytruda® and Tecentriq® is inevitable.!2:3 Our approach is designed to address drug resistance. REQORSA Immunogene Therapy may be complementary with targeted drugs and mmunotherapies. REQORSA's multimodal activity may block emerging bypass pathways,
Slide 15: AACR 21: Reqorsa + Tagrisso Reduce Tumor Growth
AACR 21: Reqorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors Enhanced Anti-Tumor Activity ‘Osimertinib+TUSC2 combination on Osimertiib+TUSC2 combination on HI975-O8iR tumors in NS mice 1H1975 tumors in NSG mice REQORSA in combination with Tagrisso demonstrated we a & 400 significant
Slide 16: Acclaim-1: Reqorsa with Tagrisso for NSCLC
© FDA Fast Track Designation © Patients with advanced, EGFR mutant NSCLC whose disease sifiews progressed after Tagrisso® Ab | i i © ~15-20 US. sites ae leet Acclaim -1 Phase 1 Dose Escalation: 12 patients (completed) ¢ Phase 2a Expansion: ~66 patients in 2 cohorts (opening for enrollment inJan. 202
Slide 17: Acclaim-1 Phase 1 Dose Escalation Results
Phase 1 Dose Escalation 006 mora 0.09mahkg OZ mphg Total: Patents 3 ” EN 2 Me on 2 us 39 Median Age (ange) 59(50-60) 518-69) 9457-74) 5938-74) outs ° ° ° ° Progression Free Survival by Dose Group PES (days) 008 8 8g - 99 009 8 8 0012 g = I Excellent safety profile and efficacy in relapsed patients.
Slide 18: Reqorsa with Immunotherapies
Regorsa® with Immunotherapies Percent Survival Survival on Lung Metastasis Model — Control 200) — PD1+CTLAS REQORSA REQORSA+PD1 — REQORSA+PD1+CTLAS a> 50 0 10 15 20 25 Days REQORSA+anti-PD1 exhibit greater anti-tumor activity than either agent alone or control. © Genprex: REQORSA+anti-PD1 combinatio
Slide 19: Reqorsa + Keytruda Increases Immune Response
Regorsa® + Keytruda® REQORSA increases immune response Significantly Reduced Tumor Eig Hl) SWEETS Growth REQORSA + Keytruda® The independent immunologic effects of REQORSA and Keytruda markedly decrease tumor growth by increasing the immunologic attack on the tumor compared to PD-1 inhibition alone.
Slide 20: AACR 21: Reqorsa May Enhance First-Line Standard of Care
AACR 21: Reqorsa® May Enhance First-Line Standard of Care Triple treatment on A549 lung metin humanized mice Reqorsa® +Keytruda@ + Chemo samy ssa eqonsa | 3 ante | + EarbosPembro z . CarbePemosREQORSA ‘© REQORSA enhances the efficacy of ZF mo i 3 chemo-immunotherapyonKRAS-LKB1 3 3 (KL)-mutant lung m
Slide 21: Acclaim-2: Reqorsa with Keytruda for NSCLC
© FDA Fast Track Designation Patients with advanced NSCLC whose disease progressed after A i | i treatment with Keytruda® . © ~10US. sites 2 eopetens Acclaim - 2 ‘o Phase 1 Dose Escalation: Up to 18 patients © Phase 2a Expansion: 36 patients o Phase 2b Randomized: 126 patients © Phase 2b interim ana
Slide 22: Reqorsa in Small Cell Lung Cancer
Regorsa® in Small Cell Lung Cancer Targeting Small Cell Lung Cancer (in addition to NSCLC) allows Genprex® to address virtually the entire lung cancer market. Small Cell Lung Cancer: © Consistently has low TUSC2 protein levels © Documented to often have deletion of at least one TUSC2 gene allele. ‘S
Slide 23: SCLCs Express Low Levels of TUSC2 Protein
SCLCs Express Low Levels Of TUSC2 Protein IHC analysis of tumor specimens Since all SCLCs have reduced or no TUSC2 protein expression, re-expressing TUSC2 © 41% of SCLC have no TUSC2 protein expression protein may lead to clinical efficacy. © 100% of SCLC have reduced or no TUSC2 protein expression
Slide 24: Atezolizumab (Tecentriq) SCLC Approval Trial
Atezolizumab (Tecentriq®) SCLC Approval Trial IMpower133 Study Adding Tecentriq to standard therapy improves survival in SCLC and establishes a new standard therapy for ES-SCLC. -o Untreated, extensive stage SCLC -© Carboplatin & etoposide chemotherapy + atezolizumab or placebo + 4cycles, then atezo
Slide 25: Atezolizumab Maintenance Therapy
Atezolizumab Maintenance Therapy Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very short (2.6 mos). © Atezolizumab vs placebo + AILCR, PR, and SD patients received maintenance therapy + Endpoints measured from the start of maintenance therapy © PFS 2.6 vs 1.8
Slide 26: Acclaim-3: Reqorsa with Tecentriq for SCLC
Fast Track Designation and Orphan Drug Designation “| i ia « Patients with ES-SCLC who did not develop tumor progression ote after receiving Tecentriq® and chemotherapy A | . 4 eee! cclaim © ~62 patients Phase 1 Dose Escalation: Up to 12 patients (opening for enrollment inJan. 2024) e Phase 2: ~50 p
Slide 27: AACR 23: NPRL2 Induces Anti-tumor Activity in NSCLC
AACR 23: NPRL2 Induces Anti-tumor Activity in NSCLC Further Evidence of Oncoprex® Delivery System as a Platform for Treatment Using Tumor Suppressor Genes © Study investigated the antitumor responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC in a humanized mouse model ‘© Hu
Slide 28: Diabetes
Q DIABETES www.genprex.com
Slide 29: Diabetes: By the Numbers
Diabetes: By the Numbers 37M S966B $24B e e e e Diabetes U.S.+ Diabetes Global? Global Diabetes T2D Global Market T1D Global Market Prevalence Prevalence Expenditures (6.7% CAGR?) (17.2% CAGR*) 96M US. adults (38% sd to rise to 643M by 316% increase in global $57B expected US. $20.38 expected US. po
Slide 30: Diabetes can cause serious complications
O Genprex Diabetes can cause serious complications. In 2021, there was approximately 1 death every 5 seconds caused by diabetes worldwide.
Slide 31: Diabetes Causes Serious Complications
Diabetes Causes Serious Complications Heart Disease Leading cause of death for men and women in USS. Diabetics are 2x as likely to have heart disease or a stroke. Chronic Kidney Disease Approximately 1 in 3 adults with diabetes have CKD. Kidney diseases are the 9th leading cause of deathin US. Nerve
Slide 32: Diabetic Patients Are In Need of Advanced Therapy
Diabetic Patients Are In Need of Advanced Therapy islets of Langerhans Recombinant produce insulin and DNA techniques the destruction of produce these cells resulted synthetic indiabetes “human insulin Insulin first introduced to Type | diabetes 1901 aol 1978 = ° The most significant advancement in
Slide 33: Novel Gene Therapy Collaboration with University of Pittsburgh
Novel Gene Thera py Collaboration with University of Pittsburgh Diabetes Program intends to address both T1D and T2D. 37.3M or 11.3% of Americans Have Diabetes* Type 1 Diabetes (5-10%) o—_—— Type 2 Diabetes (90-95%) Inability of the pancreas to produce enough insulin due largely to resistance to ins
Slide 34: GPX-002 Replenishes Levels Of Insulin
GPX-002 Replenishes Levels Of Insulin Delivers Genes to the Pancreas Anovel infusion process: Pdx1 + MafA(PM) genes t ‘an AAV vector to deliver the Reprograms Alpha Cells transforms alpha cells Restores Blood Glucose Levels In vivo, preclinical show that 6PX-002 restored normal blood glucose levels
Slide 35: Reversed Drug-Induced Diabetes in T1D Mouse Model
Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model © Genprex es 2 3 2 oe it neice: z § po = 3 an 3 z ern i ‘ a eS tot ol ies stem Ab econ ea heal Contato ta = Reprogramed alpha cells into beta-like cells that appropriately produce insulin in response to glucose levels. Normalized blood
Slide 36: Restored Blood Glucose in T1D Autoimmune Mouse Model
Restored Blood Glucose in T1D Autoimmune Mouse Model for Four Months The duration of restored blood glucose levels in mice could potentially translate to decades in humans. 10 f 600 fi i ft — . J aH 400 © One week in a mouse tends to correlate to about one year in humans. Blood glucose (mg/l) beta c
Slide 37: Induced Generation of Functional Insulin Expressing Cells from Alpha Cells
Induced Generation of Functional Insulin Expressing Cells from Alpha Cells in Human Islets Provides a potential basis for further investigation in human Type 1 diabetes © Human islets treated with streptozotocin 00 a) to destroy beta-cells, then treated with either AAV-PM or AAV-GFP © AAVtreatedisle
Slide 38: Reduced Insulin Requirements in NHP Model of T1D
in NHP 1 insulin / Carb, Primate = cil Nh, ul Lillia xia Model of T1D EE Reduced Insulin Requirements Vira Infusion MEP2 pense E nal he iia Preliminary data from University of Pittsburgh researchers show a marked reduction in insulin requirements. © Genprex
Slide 39: ATTD 23: Statistically Significant Decreases In Insulin Requirements in NHPs
ATTD 23: Statistically Significant Decreases In Insulin Requirements in NHPs Following the pancreatic intraductal infusion of the AAV a \ Average Insulin Requirements engineered construct, the eight NHPs had: -® Pre Gene Therapy © Decreased insulin requirements “Post Gene Therapy (3 months) (p<0.001
Slide 40: Corporate
a) CORPORATE www.genprex.com
Slide 41: Our Team: Company Management
Our Team: Company Management Rodney Varner, JD Chairman. President & ‘Chit Executive Offcer Catherine Vaczy, JD Executive VP. General Counsel 8 Chief Strategy Offer | Ryan Confer, MS Chief Financial Offcer Mark S. Berger, MD Chief Medical Offcer 20+ yearsofexperzeio ‘corporate lv, ncluding corporate
Slide 42: Our Team: Company Management
Our Team: Company Management Senior Vice President,
Slide 43: Our Team: Scientific Advisory Board
Our Team: Scientific Advisory Board Jack A. Roth MO, FACS, Chaieman TonyS. K. Mok IMO, FRCP(O), FHKCP, FHKAM Pasi Antero Janne MO, Pho George Simon MO George K. Gittes Mo Professor and Bud Johnson DisenguishesCincl Chair, Deparement of Thoracicand Cardiovascular Surgery, Cie ‘Section of Thorac Molec
Slide 44: Our Team: Clinical Advisory Board
Our Team: Clinical Advisory Board \ ) Michael Morse MO, MHS, FACP Andrew Becker MO, Pho Col. George Peoples MO. FACS Professor of Medicine, Dtision of Meshal Oncology Depanmentof Surgery ‘Duke University fRezeorcherperise in targeted therapies end lmmunotherapies for cancer Presiden and Founder, Bec
Slide 45: Our Team: Board of Directors
Our Team: Board of Directors (6 ;: } Rodney Vamer, JD Jose A. Moreno Toscano William R. Wilson. Jr. Brent Longnecker James E. Rothman, PhD ‘chairman of the Board Board Director Board Director Board Director Strategic Advisor tothe Board 30+ yearsofexperssein Chief Executve Office, LFB Chief Executiv
Slide 46: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones stilt Acclaim -1 Present full data from Phase 1 portion of the trial at the 2023 AACR. NCLEORTC meeting Opening for enrollmentin Phase 2a Expansion portion of the trial in jan, 2024 Complete enrollment of 19 patientsin each cohort of Phase 2a Expansion portion of t
Slide 47: We believe in a future of transformational patient care
er Caan We believe in a future of transformational patient care. 21% Century Large Combination Three FDA Gene Markets & Trials with Top Fast Track Therapies UnmetNeed | SellingDrugs | Designations Exploring New Indications & Partnerships
Slide 48: Slide 48
Slide 49: References
Research References Slide 12 1, Selective and Preferential Cancer Cell Uptake and Anti-Cancer Actity In ‘Advanced Lung Cancer Patients. Lu etal. PLoS1 (2012) Slide 13 1._American Cancer Society (2023): httos:/bit V/3SPCMRi 2. World Health Organization (2022) httos//bit.W/3fL.GVS! 3. Fortune Business
Slide 50: References
Research References Slide 32 Slide 57 (Appendix) 1, American Diabetes Association: itps/ diabetes org/blg/history wonderful 1. Phase! Clinical Tralof systemically Administered TUSC2FUSI)-Nanopartiles hing.we-calineulin Mediating Functional Gene Transferin Humans Lu Stewart Lee iL. Ramesh R etal. (20
Slide 51: Appendix
a APPENDIX www.genprex.com
Slide 52: ONC-001 & ONC-002
ONC-001 & ONC-002 DOSE ESCALATION STUDY (ONC-001) Favorable safety profile after being treated in more than 50 patients. Metabolicresponsesiin late-stage metastatic lung cancer patient Regorsa® Monotherapy & Regorsa® + Tarceva Combination REQORSA + TARCEVA (ONC-002) Ph 2 datain subjects with or with